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Raja Samir Khan1, Harris Hameed2, Ramsha Ali Bhutta3, Abdul Nafey Kazi3* and Haris Riaz4Histone de-acetylase proteins or lysine de-acetylases,
represent a group of enzymes regulating DNA and gene
expression by eliminating acetyl groups (de-acetylation)
from lysine amino acids on histones and non-histone
proteins [1,2]. Histone de-acetylase functions normally
by being involved in a series of cellular pathways like cell
growth, cell cycle, signal transduction, notch signaling
pathway and especially transcription [3]. Although these
functions allows histone de-acetylases to control expres-
sion of proteins involved in cancer initiation and cancer
progression, abnormal acetylation of histone tails may
occur with the resulting transcriptional lesions disrupting
the apoptotic program of cells and leading to neoplasia
[4,5]. To counter, development of antineoplastic agents
called histone de-acetylase inhibitors (HDIs) have been in-
troduced to interact with the catalytic site and blocking
substrate access of histone de-acetylases in proliferation of
tumor cells [6]. This anti-proliferative effect of HDIs in
down regulation of BMI1 and c-MYC protein levels has
shown promising results in treatment of the incurable
AML as well as silencing estrogen receptor alpha in pre-
vention of breast cancer [7,8].
The precise molecular actions of HDIs are unclear
with epigenetic pathways the proposed mechanism [9].
HDIs mainly induce activation of both intrinsic and
extrinsic apoptotic pathways of neoplastic cells by affect-
ing protein stability, protein-protein interactions through
interference with the function of cell cycle proteins such
as p21, inhibition of signaling pathways implicated with
Raf/MEK and activation of Reactive Oxygen Species
[10,11]. In stress, HDIs acetylate DNA damage-response
proteins, such as Ku70, causing the translocation of
BAX to the mitochondria and activating apoptosis [12].
Recently they have been known to cause autophagy of
signaling pathways like mTOR, AIF which is a major de-
velopment [13]. Some studies have also shown HDIs
contributing to growth suppression of primary tumors* Correspondence: abdulnafey@hotmail.com
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reproduction in any medium, provided the orby enhancing tumor-cell’s immunogenicity via transcrip-
tional activation of MHC (1/2) proteins and suppression
of tumor angiogenesis by inhibition of hypoxia-induced
VEGF expression [14,15].
Despite the intrinsic anticancer potential, there are
noteworthy limitations of these promising antineoplastic
agents [11]. Combinations of HDIs with other cancer
modalities such as anthracyclines have been found to be
effective in pre-clinical and clinical evaluation; however,
their additive effect has also led to potential complexities
such as resistance to anthracycline (doxorubicin) in leu-
kaemia cells and augmentation of cardiac toxicity [16].
Through modulation, HDIs also reactivate some latent
viruses like human herpesvirus-6 predisposing to re-
infection [17]. However, resistance to HDACi-induced
transformed cell death, as observed in clinical trials of
human bladder carcinoma cells and prostate cancer cells
and non-specific action against a large group of Histone
de-acetylases forms the major limitations of these agents
[15]. Basis of this resistance is yet to be understood [15].
Regardless of the Food and Drug Administration
(FDA) approval of Vorinostat (SAHA) and Romidepsin
(ISTODAX) for the promising treatment of cutaneous T
cell lymphoma, usage of HDIs as mono-therapies in
other types of cancer has had moderate effects [18]. Pre-
clinical studies on cancers have concluded better synergis-
tic and additive effects of HDIs with combination of
chemotherapeutic drugs by helping improve HDIs thera-
peutic index [18]. With complete and proper understand-
ing of the major limitations of HDIs, their antitumor
efficacy can be achieved enhancing the novel use of these
anticancer drugs for the future treatments just like their
current use as mood stabilizers and anti-epileptics.Competing interests
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